已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Nasal Obstruction and Treatment With Oxymetazoline and Corticosteroids: A Randomized Clinical Trial

医学 鼻喷雾剂 布地奈德 随机对照试验 鼻腔给药 鼻子 外科 麻醉 皮质类固醇 临床试验 局部类固醇 鼻漏 羟甲唑啉 恶化 起效 粘液纤毛清除率 哮喘 血管运动性鼻炎 中止 鼻中隔 随机化
作者
Lucas Cruz,Jake Rammell,Dorina Kallogjeri,Jay F. Piccirillo,Tomilola Agboola,Katherine E. Schwetye,Lauren T. Roland,John Schneider,Nyssa Fox Farrell
出处
期刊:JAMA otolaryngology-- head & neck surgery [American Medical Association]
标识
DOI:10.1001/jamaoto.2026.3297
摘要

Importance: Prolonged use of oxymetazoline, a highly effective nasal decongestant, is associated with rebound obstruction, but previous literature has shown potential for intranasal steroids to prevent tachyphylaxis and rebound, thereby potentially allowing for long-term combined oxymetazoline/intranasal steroid use in patients with chronic nasal obstruction. Objective: To determine whether long-term combined oxymetazoline/budesonide nasal spray could alleviate the nasal obstruction associated with chronic rhinitis without inducing symptoms or histopathologic evidence of rhinitis medicamentosa. Design, Setting, and Participants: This study was a single-center, double-blind, randomized clinical trial conducted at Washington University in St Louis/Barnes Jewish Hospital from October 2024 to July 2025. Key selection criteria included adults with chronic nasal obstruction, prior failure of topical steroids, and no chronic sinusitis. Intervention: Participants used a provided nasal spray twice daily containing either oxymetazoline/budesonide or budesonide alone for 4 weeks of active treatment followed by a 3-week wean period. Ten participants underwent pretreatment and posttreatment inferior turbinate biopsies for histopathological analysis of change. Main Outcomes and Measures: The primary outcome measure is the rate of responders, defined as at least moderate improvement on the Clinical Global Impressions-Improvement scale, assessed after 4 weeks of treatment. Measures of rebound obstruction or difficulty weaning were assessed by score changes on the Clinical Global Impression-Severity scale. Results: From 87 individuals screened, 61 participants signed informed consent, and 60 participants were randomized and completed baseline assessments. Of the randomized participants, 31 participants received oxymetazoline/budesonide spray (mean [SD] age at enrollment, 46.0 [18.7] years; 18 [58.1%] female; 13 [41.9%] male), and 29 participants received budesonide alone (mean [SD] age, 51.2 [17.1] years; 17 [58.6%] female; 12 [41.4%] male). There were 24 of 29 (83%) responders to treatment in the oxymetazoline/budesonide arm, compared with 10 of 28 (36%) in the budesonide-only arm, a difference of 47 percentage points (95% CI, 25-70 percentage points). None of the participants in the oxymetazoline arm developed worsening obstruction concerning for rebound obstruction during active treatment. All successfully weaned off oxymetazoline without issue. Conclusions and Relevance: In this randomized clinical trial, there was a large and clinically meaningful greater proportion of responders in the oxymetazoline arm, without signs or symptoms of rhinitis medicamentosa during the study. All participants successfully weaned off oxymetazoline. For patients with chronic nasal obstruction failing topical steroids, chronic therapy with combination oxymetazoline/budesonide may be considered, though risks of rebound congestion with longer-term use cannot be excluded. Trial Registration: ClinicalTrials.gov Identifier: NCT06830109.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被SYX采纳,获得10
刚刚
科目三的应助被夏侯乌采纳,获得10
刚刚
桐桐的应助被腼腆的立诚采纳,获得10
刚刚
1秒前
1秒前
今后的应助被111采纳,获得10
2秒前
帝青坤灵完成签到,获得积分10
2秒前
小新star完成签到,获得积分10
3秒前
春风暮雪发布了新的文献求助30
5秒前
初景发布了新的文献求助10
6秒前
6秒前
7秒前
7秒前
8秒前
句号完成签到 ,获得积分10
9秒前
科目三的应助被麻辣小龙虾采纳,获得10
9秒前
10秒前
10秒前
科研通AI6.4的应助被赵曼琳采纳,获得10
12秒前
夏侯乌发布了新的文献求助10
13秒前
Akim的应助被飘逸小之采纳,获得10
13秒前
FashionBoy的应助被刘辞忧采纳,获得10
14秒前
聪明平灵完成签到 ,获得积分10
15秒前
SYX发布了新的文献求助10
16秒前
从容煎蛋完成签到 ,获得积分10
17秒前
Orange的应助被腼腆的立诚采纳,获得10
17秒前
18秒前
18秒前
19秒前
21秒前
22秒前
科研通AI6.3的应助被三块石头采纳,获得10
22秒前
南风向北完成签到,获得积分10
22秒前
22秒前
23秒前
23秒前
23秒前
梦寐完成签到,获得积分10
23秒前
Eourique发布了新的文献求助10
25秒前
今后的应助被zrl采纳,获得30
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184646
求助须知:如何正确求助?哪些是违规求助? 9573637
关于积分的说明 21832477
捐赠科研通 7781914
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003